“The Association of the British Pharmaceutical Industry (ABPI) trade organisation has broadly welcomed the addition of a new route to regulatory approval, but pointed out in a recent blog post that most innovative products will fall under category B – which can have reviews paused via a ‘clock stop’ – and concluded that the new system “is not particularly competitive versus the national procedure (or as favourable as compared to the European Commission Decision Reliance Procedure).” Read More